With rising demand for targeted therapies and testing access, the Asia-Pacific region is becoming a rising player in the co-development and commercialization of drug-diagnostic strategies. In under a year, Singapore has accelerated public-private partnerships to scale genomic testing, China has expanded national reimbursement for liquid biopsies, and Japan has refined its regulatory framework for companion diagnostic approvals.   

Returning for its second year, the World Liquid Biopsy & Companion Diagnostics Summit APAC will unite 100+ leaders across biopharma, diagnostics, regulation, and healthcare to drive the co-development and commercialization of affordable, scalable, and timely testing solutions. 

Spanning oncology to neurology, chronic and rare diseases, join this APAC-dedicated forum addressing the full drug-diagnostic co-development journey, where precision partnerships are formed, regional strategies aligned, and precision medicine innovation accelerated for improved patient access across the region.